Anticancer agent 73

Cat. No.:	HY-147918
CAS No.:	124811-87-6
Molecular Formula:	$C_{14}H_{15}NO_4$
Molecular Weight:	261.27
Target:	DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (382.75 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.8275 mL	19.1373 mL	38.2746 mL
	5 mM	0.7655 mL	3.8275 mL	7.6549 mL
	10 mM	0.3827 mL	1.9137 mL	3.8275 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo[1].

In Vitro

Anticancer agent 73 (compound CIB-3b) (10 μM; 6 hours) increases the expression of E-cadherin and decreases the protein expression levels of fibronectin, N-cadherin, and vimentin in SK-HEP-1 cells; inhibits the proliferation and migration of SK-HEP-1, HCCLM3 and MHCC97L cells by inhibiting miRNA biogenesis[1].

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Anticancer agent 73 (10, 25 and 50 mg/kg; IV, every 2 days for 4 weeks) attenuates the proliferation and migration of SK-HEP-1 and SK-HEP-1 implanted in SCID mice[1] MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Peng T, et al. Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction against Hepatocellular Carcinoma via the Modulation of microRNA Biogenesis. J Med Chem. 2022 Jun 13.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA